公司資料
Exelixis 股價、新聞與催化劑
- 股票代碼:
- EXEL
- 交易所:
- NASDAQ
- 產業:
- Small Molecule Drugs
- 所在地:
- United States
股票表現
52.32 USD (+2.11%)
收盤價
最後更新: 2026年8月17日
12.2B USD
市值
股價為何變動
As of Aug 17, 2026, EXEL closed up 2.11% at $52.32. No new same-company headline was identified in the current news window.
公司概覽
Commercial Oncology Company
Exelixis develops and commercializes therapies for genitourinary and gastrointestinal cancers. Revenue from its established cabozantinib franchise funds a broad effort to create additional oncology products and combinations.
Cabozantinib Franchise
Cabozantinib is the company’s principal commercial asset and is marketed in the United States under the CABOMETYX brand across multiple tumor types. The franchise gives Exelixis an established commercial and clinical-development infrastructure in renal, liver and thyroid cancers.
Zanzalintinib Franchise
Zanzalintinib is a next-generation tyrosine kinase inhibitor being studied in numerous pivotal and signal-seeking trials. The program includes combinations with atezolizumab, WELIREG and chemotherapy across colorectal, renal, lung, prostate and other cancers.
Colorectal Cancer Registration
An NDA is under FDA review for zanzalintinib plus atezolizumab in previously treated metastatic colorectal cancer. The filing is supported by the Phase 3 STELLAR-303 trial, which demonstrated an overall-survival benefit versus regorafenib in the intent-to-treat population.
Broad Clinical Expansion
The portfolio includes the Phase 3 STELLAR-304, STELLAR-311, STELLAR-316 and LITESPARK-034 studies, as well as Phase 2 programs in recurrent meningioma and planned work in lung cancer. This breadth is intended to establish zanzalintinib as a second major Exelixis franchise.
未來催化劑
- Final STELLAR-303 overall-survival analysis in patients without liver metastases expected in mid-2026, subject to event timing.
- Initiation of the Phase 3 STELLAR-316 trial expected in mid-2026.
- Topline results from the Phase 3 STELLAR-304 trial expected in the second half of 2026.
- FDA action on the zanzalintinib-plus-atezolizumab NDA expected by December 3, 2026.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。